Skip to main content
David B. Darr on Muck Rack

David B. Darr

As seen in: Genome Medicine, Cell Press, 3BL Media, FinanzNachrichten.de, Central Charts, Republic of Green
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with David B.

Contact David B., search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Food Businesses: The Most Impactful Scope 3 Emissions Solutions Have Multiple Benefits

|
By David B. Darr, Magnum Hermosa
| deleciousfood.com
(MENAFN- 3BL Media Inc) originally published by Sustainable Brands By David Darr One of the most complex issues with accounting for greenhouse gases in our country’s food and beverage supply chains relates to scope 3 emissions and potential solutions. As companies of all sizes strive to meet their climate targets by 2030 or later, we all have a role to play in mitigating the climate crisis. One way to do this is to address our scope 3 broadcasts with solutions with multiple environmental benefits.
Open in Who Shared View Duplicates (2) Issue with article?

Vanguard Renewables: Food Companies: The Most Impactful Scope 3 Emissions Solutions Have Multiple Benefits

|
By David B. Darr
| FinanzNachrichten.de
Originally published by Sustainable Brands By DAVID DARR NORTHAMPTON, MA / ACCESSWIRE / July 6, 2023 / One of the most complicated issues with greenhouse gas accounting in our nation's food and beverage supply chains is Scope 3 emissions and the potential solutions. With companies of all sizes working to reach their climate goals by 2030 or later, we all have a role to play in mitigating the climate crisis.
Open in Who Shared View Duplicates (12) Issue with article?

Identification of Jun loss promotes resistance to histone deacetylase inhibitor entinostat through Myc signaling in luminal breast cancer

|
By Maki Tanioka, Kevin R. Mott, Daniel P. Hollern, David B. Darr
| Genome Medicine Verified
Maki Tanioka1, 2, Kevin R. Mott1, Daniel P. Hollern1, Cheng Fan1, David B. Darr1, 3 and Charles M. Perou1, 2Email author Genome Medicine201810:86 https://doi.org/10.1186/s13073-018-0597-3 ©  The Author(s). 2018 Received: 5 September 2018 Accepted: 8 November 2018 Published: 30 November 2018 Abstract Background Based on promising phase II data, the histone deacetylase inhibitor entinostat is in phase III trials for patients with metastatic estrogen receptor-positive breast cancer.
Open in Who Shared Issue with article?
See all 9 licensed articles (10 Total)